Question explored with the scientific record
Conversation so far
- 1 Is there a place for Flecanide in the treatment of my Atrial Fibrillation
- 2 Are there any newer drugs which have a role in the treatment of this condition
Answered on this page ↓
Are there any newer drugs which have a role in the treatment of this condition
The newer drugs for atrial fibrillation fall into two categories: antiarrhythmics for rhythm control and direct oral anticoagulants (DOACs) for stroke prevention. The evidence shows real benefits but also real limits.
For rhythm control, the newer drugs are dronedarone, dofetilide, and vernakalant. Dronedarone was designed to be a safer amiodarone, but the trade-off is lower efficacy. In the DIONYSOS trial, dronedarone had a 75% failure rate (AF recurrence or early discontinuation) versus 59% for amiodarone over 12 months [3]. A 2020 meta-analysis found dronedarone reduced AF recurrence by 28% compared to placebo, but it was 30% worse than amiodarone or propafenone [2]. The ANDROMEDA trial was stopped early because dronedarone increased mortality in heart failure patients [1]. Dofetilide converts AF to sinus rhythm in about 30% of patients at the highest dose, and maintains sinus rhythm in 58% at one year, but it requires hospital initiation with continuous ECG monitoring because of a 3% risk of torsade de pointes [4, 5]. Vernakalant, given intravenously, converts recent-onset AF within 90 minutes in about 51% of patients versus 4% with placebo, but it is not an oral maintenance drug [1].
For stroke prevention, the DOACs (dabigatran, rivaroxaban, apixaban, edoxaban) are genuinely newer and better than warfarin. A 2017 network meta-analysis found they reduce stroke or systemic embolism by 18-35% compared to warfarin, with lower major bleeding for apixaban (29% reduction) and lower intracranial hemorrhage across all DOACs (about 50% reduction) [10, 6]. The catch: DOACs increase gastrointestinal bleeding, especially dabigatran 150 mg and rivaroxaban [9]. The evidence comes from large industry-funded trials (RE-LY, ROCKET AF, ARISTOTLE, ENGAGE AF) that compared DOACs to warfarin, not to placebo or no treatment [7]. For patients who cannot take anticoagulants, left atrial appendage closure devices like WATCHMAN are an option, but the PROTECT AF trial showed non-inferiority to warfarin, not superiority [8].
| Drug | What it does | Key efficacy | Key safety concern |
|---|---|---|---|
| Dronedarone | Maintain sinus rhythm | 28% fewer recurrences vs placebo [2] | Increased mortality in heart failure [1] |
| Dofetilide | Convert and maintain sinus rhythm | 58% in sinus rhythm at 1 year [4] | 3% torsade de pointes; hospital initiation required [5] |
| Vernakalant (IV) | Convert recent-onset AF | 51% conversion in 90 min [1] | Fewer tachyarrhythmias than amiodarone [1] |
| DOACs (all) | Prevent stroke | 18-35% fewer strokes vs warfarin [10] | Increased GI bleeding with some agents [9] |
My call: DOACs are a genuine advance over warfarin for stroke prevention, with a clear net benefit. The newer rhythm-control drugs are less impressive: they work but are not clearly better than older options, and each carries its own serious safety limits. Confidence: moderate for DOACs, low for newer antiarrhythmics.
Sources used 10
-
Antiarrhythmic drugs for the maintenance of sinus rhythm: Risks and benefits
This review article assesses the risks and benefits of current and emerging antiarrhythmic drugs for maintaining sinus rhythm in atrial fibrillation, highlighting amiodarone’s efficacy and toxicity, the roles of dronedarone and vernakalant, and the need for individualized guidel…
DOI: 10.1016/j.ijcard.2011.06.012 -
Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis
In adults with persistent AF and minimal or no structural heart disease, dronedarone and flecainide show similar efficacy for maintaining sinus rhythm after cardioversion, with direct comparative evidence limited and nonsignificant.
DOI: 10.1093/ehjcvp/pvaa018 -
A Short‐Term, Randomized, Double‐Blind, Parallel‐Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study
This randomized, double-blind comparison of dronedarone versus amiodarone in patients with persistent atrial fibrillation found that amiodarone reduced AF recurrence more effectively over 12 months, but dronedarone offered a better safety profile with fewer thyroid/neurologic ev…
DOI: 10.1111/j.1540-8167.2010.01764.x -
Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter
In SAFIRE-D, oral dofetilide was tested in patients with chronic atrial fibrillation or atrial flutter to convert to sinus rhythm and maintain it for 1 year, showing dose-dependent pharmacological cardioversion and improved maintenance of SR with a small proarrhythmic risk when …
DOI: 10.1161/01.cir.102.19.2385 -
Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction: Safety Aspects and Effect on Atrial Fibrillation
In patients with congestive heart failure and reduced left ventricular function, dofetilide did not affect mortality but improved conversion to and maintenance of sinus rhythm and reduced hospitalization for worsening heart failure, while increasing torsade de pointes.
DOI: 10.1111/j.1527-5299.2001.00243.x -
Candeasartan retards the progression of atherosclerosis via interferance with oxidative and inflammatory pathways
A systematic meta-analysis of 14 randomized trials including 61,942 atrial fibrillation patients found that new oral anticoagulants reduce stroke/systemic embolism and all-cause mortality versus controls or vitamin K antagonists, with lower intracranial bleeding and no overall i…
DOI: 10.1016/S0167-5273(13)70557-6 -
Direct oral anticoagulant use in nonvalvular atrial fibrillation with valvular heart disease: a systematic review
This systematic review evaluates the safety and efficacy of direct oral anticoagulants (DOACs) in patients with nonvalvular atrial fibrillation (NVAF) who also have valvular heart disease (VHD), finding that while DOACs like dabigatran, rivaroxaban, and apixaban may be safely us…
DOI: 10.1002/clc.22659 -
Stroke and thromboembolism prevention in atrial fibrillation
This article reviews current strategies to prevent stroke and systemic thromboembolism in atrial fibrillation, summarizing guideline-based anticoagulation (VKAs and DOACs), left atrial appendage closure devices, peri-procedural management for cardioversion and ablation, and key …
DOI: 10.1136/heartjnl-2019-314898 -
Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials
A synthesis of organ-specific bleeding patterns observed in large randomized trials comparing NOACs with VKAs for stroke prevention in nonvalvular atrial fibrillation, showing significant reduction in intracranial haemorrhage but variable GI bleeding across agents and doses, wit…
DOI: 10.1160/TH14-04-0346 -
Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis
This study conducts a systematic review, network meta-analysis, and cost-effectiveness analysis to compare the efficacy, safety, and costs of direct acting oral anticoagulants (DOACs) against warfarin for stroke prevention in patients with atrial fibrillation.
DOI: 10.1136/bmj.j5058